Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial on Allogeneic Cytokine-induced Killer Cell Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies

NCT00460694 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT00460694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00460694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial on Allogeneic Cytokine-induced Killer Cell Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies
Lead sponsor
Singapore General Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2006
Completion date
December 31, 2012
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, hodgkin's disease, multiple myeloma, myelodysplastic syndrome, non hodgkin's lymphoma